trial · primary record
Cemiplimab
Locally Advanced Basal Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 135 |
| Primary completion | 2030-11-13 |
| Primary endpoint | Objective Response Rate (ORR) by blinded independent central review (BICR) per Composite Response Criteria |
| Registry ID | NCT07808515 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:27.279Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07808515
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cemiplimab · compound